Roth Capital Equities Analysts Reduce Earnings Estimates for Accuray Incorporated (NASDAQ:ARAY)

Accuray Incorporated (NASDAQ:ARAY) – Equities researchers at Roth Capital reduced their Q4 2024 earnings estimates for shares of Accuray in a research report issued on Thursday, May 2nd. Roth Capital analyst J. Wittes now forecasts that the medical equipment provider will post earnings of $0.04 per share for the quarter, down from their previous estimate of $0.05. Roth Capital currently has a “Buy” rating on the stock. The consensus estimate for Accuray’s current full-year earnings is ($0.07) per share. Roth Capital also issued estimates for Accuray’s FY2026 earnings at $0.13 EPS.

A number of other research analysts have also weighed in on the stock. Roth Mkm assumed coverage on shares of Accuray in a research report on Tuesday, February 13th. They set a “buy” rating and a $9.00 target price for the company. TheStreet lowered shares of Accuray from a “c-” rating to a “d+” rating in a research report on Wednesday, February 14th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.25.

Accuray Stock Up 5.2 %

Accuray stock opened at $1.62 on Friday. The firm has a market cap of $160.66 million, a price-to-earnings ratio of -7.36 and a beta of 1.48. The company has a debt-to-equity ratio of 3.53, a current ratio of 1.58 and a quick ratio of 0.84. Accuray has a fifty-two week low of $1.51 and a fifty-two week high of $4.30. The firm has a fifty day moving average price of $2.41 and a two-hundred day moving average price of $2.61.

Accuray (NASDAQ:ARAY) last released its earnings results on Wednesday, May 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.05). The firm had revenue of $101.13 million for the quarter, compared to analyst estimates of $114.60 million. Accuray had a negative return on equity of 42.34% and a negative net margin of 4.99%. During the same period in the prior year, the firm earned $0.01 EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Heartland Advisors Inc. raised its position in shares of Accuray by 0.3% during the fourth quarter. Heartland Advisors Inc. now owns 2,857,500 shares of the medical equipment provider’s stock valued at $8,087,000 after buying an additional 9,700 shares during the last quarter. North Star Investment Management Corp. raised its position in shares of Accuray by 0.5% during the first quarter. North Star Investment Management Corp. now owns 1,100,920 shares of the medical equipment provider’s stock valued at $2,719,000 after buying an additional 5,000 shares during the last quarter. Kennedy Capital Management LLC raised its position in shares of Accuray by 8.8% during the third quarter. Kennedy Capital Management LLC now owns 995,536 shares of the medical equipment provider’s stock valued at $2,708,000 after buying an additional 80,455 shares during the last quarter. First Eagle Investment Management LLC raised its position in shares of Accuray by 5.3% during the fourth quarter. First Eagle Investment Management LLC now owns 959,508 shares of the medical equipment provider’s stock valued at $2,715,000 after buying an additional 48,583 shares during the last quarter. Finally, Acuitas Investments LLC increased its stake in Accuray by 14.7% in the fourth quarter. Acuitas Investments LLC now owns 708,553 shares of the medical equipment provider’s stock valued at $2,005,000 after acquiring an additional 91,053 shares during the period. Institutional investors and hedge funds own 64.08% of the company’s stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.